Novartis's COPD combo gets CHMP nod
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions for Novartis's chronic lung disease product Ultibro/Xoterna Breezhaler. It combines the long-acting muscarinic antagonist glycopyrronium bromide with the fast-acting beta-2 agonist indacaterol.